×
About 2,460 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  919 results

Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia i...
https://doi.org/10.1002/cncr.33914
Cancer Jamy OH, Dhir A et. al.

Sep 9th, 2021 - The survival of patients with acute promyelocytic leukemia (APL) has dramatically improved with the use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, because of the complexity of the initial management, early mortality (EM...

Diagnosis of Acute Promyelocytic Leukemia After Presentation to Neuro-Ophthalmology.
https://doi.org/10.1097/WNO.0000000000001259
Journal of Neuro-ophthalmology : the Official Journal of ... Paxton AB, Micieli JA

Sep 7th, 2021 - Acute promyelocytic leukemia (APML) is a medical emergency that can initially present with neuro-ophthalmologic signs. Early recognition is crucial, and immediate treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) can be life...

Induction of Cross-resistance to ABCB1 Substrates in Venetoclax-resistant Human Leukemi...
https://doi.org/10.21873/anticanres.15228
Anticancer Research; Nakayama Y, Takara K et. al.

Sep 4th, 2021 - Resistance to venetoclax, a selective inhibitor of BCL2 apoptosis regulator (BCL2), is regarded as a clinical problem. However, it is unclear whether resistance to venetoclax induces cross-resistance to other drugs. Venetoclax-resistant HL60/VEN c...

Differential Survival Outcomes Between De Novo and Secondary Acute Promyelocytic Leukem...
https://doi.org/10.1016/j.clml.2021.07.023
Clinical Lymphoma, Myeloma & Leukemia; Tao Y, Yu YQ et. al.

Sep 1st, 2021 - Whether the characteristics and outcome of secondary acute promyelocytic leukemia (s-APL) are similar to de no APL (dn-APL) remains unknown. Using the SEER database, we identified 3877 patients with APL diagnosed from 2000 to 2014, including 465 s...

Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics feat...
https://doi.org/10.1097/CAD.0000000000001228
Anti-cancer Drugs; Sun J, Ning S et. al.

Aug 31st, 2021 - Some previous researches raised the possibility of a novel acute myeloid leukemia (AML) entity presenting cup-like cytomorphology with mutations of both FLT3 and NPM1 or one of them. However, the clinical implications of this subtype remain unknow...

see more →

Guidelines  1 results

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  11 results see all →

News  53 results

How to Treat Differentiation Syndrome in APL and AML
https://decisionpoint.medscape.com/oncology/viewarticle/936167

Sep 18th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...

Don't Overlook Treating Older Patients With Acute Promyelocytic Leukemia, Expert Says
https://www.medscape.com/viewarticle/934124

Jul 17th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.medscape.com/viewarticle/917519

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.staging.medscape.com/viewarticle/917519

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

see more →